Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study - Top-Institutions - MDSpire

Evaluating the Prognostic Utility of Established Scoring Systems for Early Mortality in Phase I Immunotherapy Trials: A Comparative Real-World Cohort Analysis

  • By

  • Paloma Sangro

  • Ana Landa-Magdalena

  • Miguel Sogbe

  • Teresa Zumarraga

  • Ignacio Matos

  • Mariano Ponz-Sarvise

  • Marina Crespo

  • María Esperanza Rodriguez-Ruiz

  • Anna Vilalta-Lacarra

  • Eduardo Castañón

  • July 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Gustave Roussy
    Gustave Roussy

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology

  • #2

    Clínica Universidad de Navarra
    Clínica Universidad de Navarra

    Pamplona, Navarra

    Key Differentiators

    • Oncology

  • #3

    Royal Marsden Hospital
    Royal Marsden Hospital

    London, England

    Key Differentiators

    • Oncology

  • #4

    Vall d’Hebron Institute of Oncology
    Vall d’Hebron Institute of Oncology

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

  • #5

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study

  • by Paloma Sangro, Ana Landa-Magdalena, Miguel Sogbe, Teresa Zumarraga, Ignacio Matos, Mariano Ponz-Sarvise, Marina Crespo, María Esperanza Rodriguez-Ruiz, Anna Vilalta-Lacarra, Eduardo Castañón

  • July 20, 2026

Related Content

Long-term risk of gynecologic malignancies in postmenopausal women with vaginal bleeding and benign endometrial lesions: a cohort study

Global research landscape and hotspots of paraptosis: a multi-database bibliometric analysis with a focused literature review

STMN1 expression is associated with chemotherapy and immunotherapy efficacy in biliary tract cancer